Paula Amat

Paula Amat

Auto-generated profile, based on publicly available information

Paula Amat

Hospital Clínico Universitario de Valencia Valencia Spain

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2024 in Clinical Neurophysiology
Verified
Journal Article
Open access
RHRafael Hernani
Rafael Hernani
MAMika Aiko
Mika Aiko
RVRuth Victorio
Ruth Victorio
ABAna Benzaquén
Ana Benzaquén
APAriadna Pérez
Ariadna Pérez
CSCarlos Solano
Carlos Solano
Immune effector cell-associated neurotoxicity syndrome (ICANS) is common after chimeric antigen receptor T-cell (CAR-T) therapy. This study aimed to assess the impact of preinfusion electroencephalography (EEG) abnormalities and EEG findings at ICANS onset for predicting ICANS risk and severity in 56 adult patients with refractory lymphoma undergoing CAR-T therapy. EEGs were conducted at the time of lymphodepleting chemotherapy and shortly after onset of ICANS. Twenty-eight (50%) patients developed ICANS at a median time of 6 days after CAR-T infusion. Abnormal preinfusion EEG was identified as a risk factor for severe ICANS (50% vs. 17%, P = 0.036). Following ICANS onset, EEG abnormalities were detected in 89% of patients [encephalopathy (n = 19, 70%) and/or interictal epileptiform discharges (IEDs) (n = 14, 52%)]. Importantly, IEDs seemed to be associated with rapid progression to higher grades of ICANS within 24 h. If confirmed in a large cohort of patients, these findings could establish the basis for modifying current management guidelines, enabling the identification of patients at risk of neurotoxicity, and providing support for preemptive corticosteroid use in patients with both initial grade 1 ICANS and IEDs at neurotoxicity onset, who are at risk of neurological impairment.


13 September 2019 in Anticancer Research
Verified
Journal Article
Open access
PDF file
IMIván Martín
Iván Martín
BNBlanca Navarro
Blanca Navarro
CSCarlos Solano
Carlos Solano
MCMarisa Calabuig
Marisa Calabuig
JBJuan Carlos Hernández Boluda
Juan Carlos Hernández Boluda
MDMar Tormo Diaz
Mar Tormo Diaz
Background/Aim: Azacitidine (AZA) is a hypomethylating agent used in myeloid neoplasms, however, approximately half of patients show treatment failure or relapse. This in vitro study investigated the effect of the combination of AZA with the natural compound curcumin (CUR) in increasing its efficacy. Materials and Methods: We analyzed the effects of AZA plus CUR on proliferation, apoptosis, cell cycle and differentiation in myeloid leukemic cell lines (U-937, HL-60, K-562, and OCI-AML3) and bone marrow samples of patients. Results: The results showed a synergy between AZA and CUR in all leukemic lines and in most leukemic samples, with a decrease in proliferation and an increase in apoptosis compared to the activity of each drug separately. In addition, AZA plus CUR showed low cytotoxicity in healthy samples. Conclusion: A remarkable antioncogenic effect of the combination of AZA plus CUR was shown, providing a basis for future studies analyzing the clinical efficacy of these drugs.

19 March 2015 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
EGEstela Giménez
Estela Giménez
CSCarlos Solano
Carlos Solano
PAPaula Amat
Paula Amat
RCRafael de la Camara
Rafael de la Camara
JNJosé Nieto
José Nieto
DNDavid Navarro
David Navarro